Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glecaprevir/Pibrentasvir in Treatment-Naïve Chronic HCV with APRI ≤ 1
NCT03212521Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2017
- Primary completion
- Aug 2018
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 10
01
Overview
A Phase 3 trial of glecaprevir, pibrentasvir in hepatitis C (HCV), sponsored by AbbVie Inc.. Started Aug 2017; status: completed.
02
Drugs
glecaprevirpibrentasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03212521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03212521.